Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

38

Revenue 2017

Imbruvica

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Imbruvica was produced by Johnson & Johnson.

AstraZeneca’s Calquence impresses in previously untreated CLL

AstraZeneca’s Calquence impresses in previously untreated CLL Now, AZ will have to convince clinicians to prescribe Calquence rather than its rival Imbruvica (ibrutinib) from AbbVie/Johnson &Johnson. ... AbbVie has also stacked new data for Imbruvica, unveiling a combination of the therapy with Roche’s Venclexta

AstraZeneca wins FDA approval for Calquence in chronic lymphoma

AstraZeneca wins FDA approval for Calquence in chronic lymphoma and small lymphocytic lymphoma (SLL), taking the fight to AbbVie/Johnson &Johnson’s Imbruvica. . ... Now that it has approvals in CLL and SLL, AZ will hope to see it’s market share grow exponentially – if it can compete with rival Imbruvica

BeiGene bags FDA approval for first product Brukinsa in lymphoma

BeiGene bags FDA approval for first product Brukinsa in lymphoma The new approval positions BeiGene’s drug as a rival to AbbVie/Johnson &Johnson’s well-established BTK inhibitor Imbruvica (ibrutinib), which is already approved for several haematological disorders – including ... First-to-market Imbruvica made

Litigation concerns threaten to overshadow solid quarter at J&J

Litigation concerns threaten to overshadow solid quarter at J&J Growth for immunology therapy Stelara (ustekinumab) and blood cancer drugs Imbruvica (ibrutinib) and Darzalex (daratumumab) – plus Stelara follow-up Tremfya (guselkumab) – outweighed the effect of generic competition to older prostate cancer

BeiGene gets speedy US review for lymphoma drug zanubrutinib

BeiGene gets speedy US review for lymphoma drug zanubrutinib BeiGene is trying to position zanubrutinib as a rival to AbbVie/Johnson &Johnson’s well-established BTK inhibitor Imbruvica (ibrutinib), which is already approved for several haematological disorders – including CLL, MCL ... Calquence made $64m in

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics